<PARTICULARS TO APPEAR ON THE OUTER PACKAGE>

{Carton} Blister

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Lepitil 60mg Flavoured Tablets for Dogs
Phenobarbital

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each tablet contains:
Phenobarbital 60mg

3. PHARMACEUTICAL FORM

Tablet.

4. PACKAGE SIZE

10 tablets
20 tablets
30 tablets
40 tablets
50 tablets
60 tablets
70 tablets
80 tablets
90 tablets
100 tablets
500 tablets
1000 tablets

5. TARGET SPECIES

Dogs

6. INDICATION(S)

Read the package leaflet before use.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.
The tablets can be divided into two or four equal parts.Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.
People with known hypersensitivity to barbiturates should avoid contact with the veterinary medicinal product. Accidental ingestion may cause intoxication and could be fatal, particularly for children. Take utmost care that children do not come in contact with the product

10. EXPIRY DATE

Shelf life of divided tablets: 2 days
EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

Store the blisters in the original container.
If the tablets are divided, the remaining tablets portion should be returned to the blister pack.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

POM

Prescription Only Medicine

14. THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
Ireland

16. MARKETING AUTHORISATION NUMBER

Vm 08749/4033

17. MANUFACTURER'S BATCH NUMBER

BN

<PARTICULARS TO APPEAR ON THE OUTER PACKAGE>

{Carton} Duma

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Lepitil 60mg Flavoured Tablets for Dogs

Phenobarbital

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each tablet contains:
Phenobarbital 60mg

3. PHARMACEUTICAL FORM

Tablet.

4. PACKAGE SIZE

100 tablets
500 tablets

5. TARGET SPECIES

Dogs

6. INDICATION(S)

Read the package leaflet before use.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use.
The tablets can be divided into two or four equal parts.Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.
People with known hypersensitivity to barbiturates should avoid contact with the veterinary medicinal product. Accidental ingestion may cause intoxication and could

be fatal, particularly for children. Take utmost care that children do not come in contact with the product

10. EXPIRY DATE

Shelf life of divided tablets: 2 days
EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

Store the tablets in the original container.
If the tablets are divided, the remaining tablets portion should be returned to the original container.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.
POM
Prescription Only Medicine

14. THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
Ireland

16. MARKETING AUTHORISATION NUMBER

Vm 08749/4033

17. MANUFACTURER'S BATCH NUMBER

BN

<PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE>

{Label} DUMA

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Lepitil 60mg Flavoured Tablets for Dogs
Phenobarbital

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each tablet contains:
Phenobarbital 60mg

3. PHARMACEUTICAL FORM

Tablet

4. PACKAGE SIZE

100 tablets
500 tablets

5. TARGET SPECIES

Dogs

6. INDICATION(S)

Read the package leaflet before use.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Oral use
The tablets can be divided into two or four equal parts.Read the package leaflet before use.

8. WITHDRAWAL PERIOD

Not applicable.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.
Smaller quantities dispensed from a bulk pack should be supplied in a container with a child resistant closure.

10. EXPIRY DATE

Shelf life of divided tablets: 2 days

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

If the tablets are divided, the remaining tablet portion should be returned to the pack.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

POM

Prescription Only Medicine

14. THE WORDS "KEEP OUT OF THE REACH AND SIGHT OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd.,
Loughrea,
Co. Galway,
Ireland

16. MARKETING AUTHORISATION NUMBER

Vm 08749/4033

17. MANUFACTURER'S BATCH NUMBER

BN

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

{NATURE/TYPE}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Lepitil 60mg Flavoured Tablets for Dogs
Phenobarbital

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

3. EXPIRY DATE

EXP {month/year}

4. BATCH NUMBER

BN {number}

5. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

B. PACKAGE LEAFLET

PACKAGE LEAFLET
Lepitil 60mg Flavoured Tablets for Dogs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing Authorisation Holder and manufacturer responsible for release
Chanelle Pharmaceuticals Manufacturing Ltd.
Loughrea,
Co. Galway,
Ireland.

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Lepitil 60mg Flavoured Tablets for Dogs
Phenobarbital

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each tablet contains:
Active substance:
Phenobarbital 60 mg

White, circular tablet with cross breakline on one side
The tablets can be divided into two or four equal parts.

4. INDICATION(S)

Prevention of seizures due to generalized epilepsy in dogs.

5. CONTRAINDICATIONS

Do not use in animals with serious impaired hepatic function.
Do not use in animals with serious renal or cardiovascular disorders.
Do not use in dogs weighing less than 6 kg body weight.
Do not use in case of hypersensitivity to the active substance or to any other barbiturates or to any of the excipients.

6. ADVERSE REACTIONS

All adverse effects noted below have been reported very rarely.During start of therapy ataxia, and sedation can occur but these effects are usually transitory and disappear in most, but not all, patients with continued medication. Some animals can demonstrate a paradoxical hyperexcitability, particularly after first starting therapy.

As this hyperexcitability is not linked to overdosage, no reduction of dosage is needed. Polyuria, polydipsia and polyphagia can occur at average or higher therapeutic active serum concentrations; these effects can be diminished by limiting intake of both food and water. Sedation and ataxia often become significant concerns as serum levels reach the higher ends of the therapeutic range. High plasma concentrations may be associated with hepatotoxicity. Phenobarbital can have deleterious effects on stem cells from bone marrow. Consequences are immunotoxic pancytopenia and/or neutropenia. These reactions disappear after the treatment's withdrawal. Treating dogs with phenobarbital may lower their TT4 or FT4 serum levels, however this may not be an indication of hypothyroidism. Treatment with thyroid hormone replacement should only be started if there are clinical signs of the disease.
If adverse effects are severe, the decrease in the administered dose is recommended.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports)

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

For oral administration.
The required dosage will differ to some extent between individuals and with the nature and severity of the disorder.

Tablets must be given at the same time each day and should be co-ordinated with feeding times in a consistent manner to optimise treatment success.

Dogs should be dosed orally, starting with a dose of 2-5mg per kg bodyweight per day. The dose should be divided and administered twice daily.

Steady state serum concentrations are not reached until 1-2 weeks after treatment is initiated. The full effect of the medication does not appear for two weeks and doses should not be increased during this time.

If seizures are not being controlled, the dosage may be increased by 20% at a time, with associated monitoring of serum phenobarbital levels. The phenobarbital serum concentration may be checked after steady state has been achieved, and if it is less than 15µg/ml the dose may be adjusted accordingly. If seizures recur the dose may be raised up to a maximum serum concentration of 45µg/ml. High plasma concentrations may be associated with hepatotoxicity. Blood samples could be taken

at the same time to allow plasma phenobarbital concentration to be determined preferably during trough levels, shortly before the next dose of phenobarbital is due.

Plasma concentrations should be interpreted in conjunction with the observed response to therapy and a full clinical assessment including monitoring for evidence of toxic effects in each animal.

Clinical data suggests that considerable variation in plasma concentrations of phenobarbital may be observed in some animals. This variation may result in an animal with a trough plasma concentration of phenobarbital below the typical minimum therapeutic level and a peak plasma concentration approaching the maximum level. If the seizure control is inadequate in such animals, care should be taken when increasing the dose as toxic levels may be reached or exceeded. Peak and trough plasma concentrations of phenobarbital may need to be measured in such animals. (Peak plasma concentrations are reached within approximately 3 hours after administration).

If the seizures are not being satisfactorily controlled and if the maximum plasma concentration of phenobarbital is about 40µg/ml, then the diagnosis should be reconsidered and/or a second antiepileptic product (such as bromides) should be added to the treatment protocol.

Tablets can be divided into equal halves or quarters to ensure accurate dosing.
To break a cross scored tablet into quarters, place the tablet on an even surface with the scored side up and apply pressure on the middle with your thumb.

To break a tablet into two halves, place the tablet on an even surface with the scored side up, hold one half of the tablet and press down on the other half.



9. ADVICE ON CORRECT ADMINISTRATION

Steady state serum concentrations are not reached until 1–2 weeks after treatment is initiated. The full effect of the medication does not appear for two weeks and doses should not be increased during this time.

If seizures are not being controlled the dosage may be increased by 20% at a time with associated monitoring of serum phenobarbital levels. The phenobarbital serum concentration may be checked after steady state has been achieved and if it is less than 15 microgram/ml the dose may be adjusted accordingly. If seizures recur the dose may be raised up to a maximum concentration of 45 microgram/ml.
High plasma concentrations may be associated with hepatotoxicity. Blood samples should be taken at the same time to allow plasma phenobarbital concentrations to be determined preferably during trough levels shortly before the next dose of phenobarbital is due.
Withdrawal or transition from other types of anti-epileptic therapy should be made gradually to avoid precipitating an increase in the frequency of seizures.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Unused half or quarter tablets must be used within 2 days
Keep out of the sight and reach of children.
Each time an unused part-tablet is stored until next use, it should be returned either to the open blister space and inserted back into the cardboard box or placed back into the container and kept in a safe place out of the reach and sight of children as it poses a health risk to small children due to accidental ingestion.
This veterinary medicinal product does not require any special storage conditions.
Do not use after the expiry date stated on the label and on the outer carton.

12. SPECIAL WARNING(S)

Special precautions for use in animals
Caution is recommended in animals with impaired hepatic and renal function, hypovolemia, anaemia and cardiac or respiratory dysfunction. The chance of hepatotoxic side effects can be diminished or delayed using an effective dose that is as low as possible. Monitoring of hepatic parameters is recommended in case of a prolonged therapy.

It is recommended to assess the clinical pathology of the patient 2-3 weeks after start of treatment and afterwards every 4-6 months, e.g. measurement of hepatic enzymes and serum bile acids. It is important to know that the effects of hypoxia etc. do cause increased levels of hepatic enzymes after a seizure. Phenobarbital may increase the activity of serum alkaline phosphatase and transaminases. These may demonstrate non-pathological changes, but could also represent hepatotoxicity, liver function tests are recommended. Increased liver enzyme values do not require a dose reduction of phenobarbital if the serum bile acids are in the normal range.

In stabilised epileptic patients, it is not recommended to switch from other phenobarbital formulators to Lepitil 60 mg tablets. However, if this cannot be avoided then additional caution should be taken. This includes more frequent plasma concentration sampling to ensure that therapeutic levels are maintained. Monitoring

for increased side effects and for hepatic dysfunction should be conducted more regularly until stabilisation is confirmed.
Withdrawal or transition from other types of anti-epileptic therapy should be made gradually to avoid precipitating an increase in the frequency of seizures.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals

Special precautions for the person administering the veterinary medicinal product to animals

- Barbiturates can cause hypersensitivity. People with known hypersensitivity to barbiturates should avoid contact with the product.
- Accidental ingestion may cause intoxication and could be fatal, particularly for children. Take utmost care that children do not come in contact with the product.
- Phenobarbital is teratogenic and may be toxic to unborn and breastfeeding children; it may affect the developing brain and lead to cognitive disorders. Phenobarbital is excreted in breast milk. Pregnant women, women of childbearing age and women who are breastfeeding should avoid accidental ingestion and prolonged skin contact with the product.
- Keep this product in its original packaging to avoid accidental ingestion.
- It is advisable to wear disposable gloves during administration of the product to reduce skin contact.
- In case of accidental ingestion, seek medical attention immediately, advising medical services of barbiturate poisoning; show the package leaflet or the label to the physician. If possible, the physician should be informed about the time and amount of ingestion, as this information may help to ensure that appropriate treatment is given.
- Each time an unused part-tablet is stored until next use, it should be returned to the open blister space and inserted back into the cardboard box.
- Wash hands thoroughly after use.

Interaction with other medicinal products and other forms of interaction:
Phenobarbital will potentially reduce therapeutic levels of a wide range of drugs due to its inducing effect on hepatic enzymes.

A therapeutic dose of phenobarbital for antiepileptic therapy can significantly induce plasma proteins, (such as α1acid glycoprotein, AGP), which bind drugs.
Phenobarbital may reduce the activity of some drugs by increasing the rate of metabolism through induction of drug-metabolising enzymes in liver microsomes. Therefore special attention must be paid to the pharmacokinetics and doses of drugs simultaneously administered. The plasmatic concentration of a range of drugs is decreased in the case of concurrent administration of phenobarbital.
Cimetidine and ketoconazole are inhibitors of hepatic enzymes: concurrent use with phenobarbital can induce an increase of serum concentration of phenobarbital.
Phenobarbital may decrease the absorption of griseofulvin.
Concurrent use with potassium bromide increases the risk of pancreatitis.
Concurrent use with other drugs having a central depressive action can increase the effect of phenobarbital.

Use of phenobarbital tablets in conjunction with primidone is not recommended as primidone is predominantly metabolized to phenobarbital.

Overdose (symptoms, emergency procedures, antidotes):

Symptoms of overdose are:
- depression of the central nervous system demonstrated by signs ranging from sleep to coma,
- respiratory problems,
- cardiovascular problems, hypotension and shock leading to renal failure and death.

In case of overdose remove ingested product from the stomach, for example by lavage. Activated charcoal may be given. Offer respiratory support.

There is no specific antidote, but CNS stimulants, (like Doxapram) may stimulate the respiratory centre. Give oxygen support.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements. Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

Blister (10 tablets) package sizes are 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 500 and 1000.
Duma package sizes are 100 and 500 tablets.
Not all pack sizes and/or types may be marketed.

POM
Prescription Only Medicine

Approved 04 July 2018